UY36083A - ?sistemas y métodos para mejorar la función de los órganos y la longevidad de los trasplantes de órganos?. - Google Patents

?sistemas y métodos para mejorar la función de los órganos y la longevidad de los trasplantes de órganos?.

Info

Publication number
UY36083A
UY36083A UY0001036083A UY36083A UY36083A UY 36083 A UY36083 A UY 36083A UY 0001036083 A UY0001036083 A UY 0001036083A UY 36083 A UY36083 A UY 36083A UY 36083 A UY36083 A UY 36083A
Authority
UY
Uruguay
Prior art keywords
organs
methods
function
organ transplants
systems
Prior art date
Application number
UY0001036083A
Other languages
English (en)
Inventor
Wager Jeffrey
Wager Joseph
Stenzler Alex
Original Assignee
Proterris Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proterris Inc filed Critical Proterris Inc
Publication of UY36083A publication Critical patent/UY36083A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0051—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes with alarm devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/021—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes operated by electrical means
    • A61M16/022—Control means therefor
    • A61M16/024—Control means therefor including calculation means, e.g. using a processor
    • A61M16/026—Control means therefor including calculation means, e.g. using a processor specially adapted for predicting, e.g. for determining an information representative of a flow limitation during a ventilation cycle by using a root square technique or a regression analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/12—Preparation of respiratory gases or vapours by mixing different gases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/1005—Preparation of respiratory gases or vapours with O2 features or with parameter measurement
    • A61M2016/102—Measuring a parameter of the content of the delivered gas
    • A61M2016/1035—Measuring a parameter of the content of the delivered gas the anaesthetic agent concentration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/02—Gases
    • A61M2202/0208—Oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/02—Gases
    • A61M2202/0225—Carbon oxides, e.g. Carbon dioxide
    • A61M2202/0233—Carbon monoxide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/795—Porphyrin- or corrin-ring-containing peptides
    • G01N2333/805—Haemoglobins; Myoglobins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)

Abstract

La presente invención proporciona sistemas y métodos para terapia con CO inhalado para prevenir, atenuar o retrasar los procesos que aceleran la pérdida de función de los órganos y, de esta forma, aumenta el tiempo de vida de los órganos trasplantados o ralentiza el deterioro de los órganos naturales o retrasa la necesidad de remplazar órganos naturales enfermos con trasplantes de órganos. Los procesos biológicos que se previenen, atenúan o retrasan incluyen inflamación crónica persistente, fibrosis, cicatrización, así como ataque autoinmune o inmunológico.
UY0001036083A 2014-04-15 2015-04-15 ?sistemas y métodos para mejorar la función de los órganos y la longevidad de los trasplantes de órganos?. UY36083A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461979712P 2014-04-15 2014-04-15
US201461993140P 2014-05-14 2014-05-14

Publications (1)

Publication Number Publication Date
UY36083A true UY36083A (es) 2015-11-30

Family

ID=54324546

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036083A UY36083A (es) 2014-04-15 2015-04-15 ?sistemas y métodos para mejorar la función de los órganos y la longevidad de los trasplantes de órganos?.

Country Status (11)

Country Link
US (4) US9789133B2 (es)
EP (3) EP4257201A3 (es)
JP (1) JP2017518962A (es)
CN (1) CN106455577A (es)
BR (1) BR112016024047A2 (es)
DK (1) DK3643176T3 (es)
ES (1) ES2761659T3 (es)
MX (1) MX2016013516A (es)
TW (1) TW201618795A (es)
UY (1) UY36083A (es)
WO (1) WO2015160973A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3199098B1 (en) * 2014-09-23 2024-02-07 Shenzhen Seekya Bio-Sci & Tech Co., Ltd. Method and apparatus for measuring endogenous co concentration in alveolar air
CN106124749B (zh) * 2016-02-26 2019-01-29 深圳市先亚生物科技有限公司 一种红细胞寿命测定方法及装置
US11771855B2 (en) * 2017-01-10 2023-10-03 Brian Charles Weiner Methods of treating medical conditions with oxygen
US11744643B2 (en) 2019-02-04 2023-09-05 Covidien Lp Systems and methods facilitating pre-operative prediction of post-operative tissue function

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413100A (en) 1991-07-17 1995-05-09 Effets Biologiques Exercice Non-invasive method for the in vivo determination of the oxygen saturation rate of arterial blood, and device for carrying out the method
US5558083A (en) * 1993-11-22 1996-09-24 Ohmeda Inc. Nitric oxide delivery system
US8128963B2 (en) 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
US5810723A (en) 1996-12-05 1998-09-22 Essential Medical Devices Non-invasive carboxyhemoglobin analyer
US6084661A (en) 1998-05-07 2000-07-04 Worcestor Polytechnic Institute Optical method and apparatus for measuring carbon monoxide in non-hemolyzed blood
US6542858B1 (en) * 1998-09-14 2003-04-01 Lion Bioscience Ag Pharmacokinetic-based drug design tool and method
US7678390B2 (en) * 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
US6581599B1 (en) * 1999-11-24 2003-06-24 Sensormedics Corporation Method and apparatus for delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients
US6668828B1 (en) * 2000-10-16 2003-12-30 Pulmonox Technologies Corporations System and elements for managing therapeutic gas administration to a spontaneously breathing non-ventilated patient
KR20090110362A (ko) * 2001-06-21 2009-10-21 베쓰 이스라엘 디코니스 메디칼 센터 인크 조직 및 장기 이식 결과의 개선 및 아폽토시스의 억제에 사용되는 일산화탄소
ES2316583T3 (es) * 2001-06-21 2009-04-16 Beth Israel Deaconess Medical Center, Inc. El monoxido de carbono mejora los resultados de trasplantes de tejidos y organos y suprime la adoptosis.
EP1480658B1 (en) 2002-02-13 2017-01-25 Beth Israel Deaconess Medical Center, Inc. Methods of treating vascular disease
ES2546280T3 (es) * 2002-04-15 2015-09-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Monóxido de carbono para su uso en un método para tratar íleo
RS91104A (en) 2002-04-15 2007-02-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education, Methods of treating necrotizing enterocolitis
BR0215717A (pt) * 2002-05-09 2005-02-22 Univ Yale Monóxido de carbono como um biomarcador e agente terapêutico
RS99304A (en) 2002-05-17 2007-04-10 Yale University, Methods of treating hepatitis
US20040131703A1 (en) * 2002-06-21 2004-07-08 Bach Fritz H. Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
DE10230165A1 (de) * 2002-07-04 2004-01-15 Ino Therapeutics Gmbh Verfahren und Vorrichtung zur Administration von Kohlenmonoxid
DE102004050717B8 (de) * 2004-10-19 2006-02-23 Dräger Medical AG & Co. KGaA Anästhesievorrichtung
US8893717B2 (en) * 2005-09-21 2014-11-25 Ino Therapeutics Llc Systems and methods of administering a pharmaceutical gas to a patient
US7523752B2 (en) 2005-09-21 2009-04-28 Ino Therapeutics, Llc System and method of administering a pharmaceutical gas to a patient
US8778413B2 (en) 2010-05-14 2014-07-15 Ikaria, Inc. Dosing regimens and methods of treatment using carbon monoxide
US8607791B2 (en) 2010-06-30 2013-12-17 Covidien Lp Ventilator-initiated prompt regarding auto-PEEP detection during pressure ventilation
CA2844660A1 (en) 2011-08-09 2013-02-14 Leo E. Otterbein Methods of treating dna damage
AR090339A1 (es) 2012-03-27 2014-11-05 Genentech Inc Metodos de pronostico, diagnostico y tratamiento de la fibrosis pulmonar idiopatica
JP2016537427A (ja) 2013-11-14 2016-12-01 プロテリス， インコーポレイテッド 一酸化炭素を用いた肺疾患の治療または予防

Also Published As

Publication number Publication date
US11389471B2 (en) 2022-07-19
ES2761659T3 (es) 2020-05-20
DK3643176T3 (da) 2023-09-11
US9789133B2 (en) 2017-10-17
TW201618795A (zh) 2016-06-01
CN106455577A (zh) 2017-02-22
US20150320791A1 (en) 2015-11-12
US10342821B2 (en) 2019-07-09
BR112016024047A2 (pt) 2018-08-07
EP3131401B1 (en) 2019-09-11
US20210308175A1 (en) 2021-10-07
EP3643176B1 (en) 2023-06-07
EP3131401A4 (en) 2018-01-10
EP4257201A2 (en) 2023-10-11
US20190321394A1 (en) 2019-10-24
WO2015160973A8 (en) 2016-12-01
WO2015160973A1 (en) 2015-10-22
EP4257201A3 (en) 2023-12-13
EP3131401A1 (en) 2017-02-22
JP2017518962A (ja) 2017-07-13
EP3643176A1 (en) 2020-04-29
MX2016013516A (es) 2017-08-10
US20180000859A1 (en) 2018-01-04

Similar Documents

Publication Publication Date Title
CO2019012080A2 (es) Terapias combinadas dirigidas a pd-1, tim-3, y lag-3
CL2017002567A1 (es) Composiciones para modular la expresión de c9orf72
PE20180243A1 (es) Composiciones que comprenden cepas bacterianas
CL2018000353A1 (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
CO2019004003A2 (es) Composiciones y anticuerpos anti-lag-3
CO2019002123A2 (es) Plantas y métodos para aumentar y disminuir la síntesis de cannabinoides
EA201992155A1 (ru) Способы криогенного хранения
CL2018001258A1 (es) Métodos para tratar las condiciones asociadas con la activación del complemento dependiente de masp-2
CL2017003142A1 (es) Composiciones que comprenden cepas bacterianas
PE20180267A1 (es) Composiciones que comprenden cepas bacterianas
MX2022007472A (es) Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario.
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
NZ730865A (en) Peptides having anti-inflammatory properties
AR102553A1 (es) Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit
EA201500943A1 (ru) Составы для мобилизации, хоуминга, размножения и дифференцировки стволовых клеток и способы применения составов
CO2018006297A2 (es) Composiciones y métodos para disminuir la expresión de tau
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
ECSP14030779A (es) Inhibidores del nampt
CO2017009404A2 (es) Inhibidores de calicreina plasmática y uso de los mismos para prevenir el ataque del angioedema hereditario
ECSP14000606A (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
UY36083A (es) ?sistemas y métodos para mejorar la función de los órganos y la longevidad de los trasplantes de órganos?.
EA201791703A1 (ru) Композиция для повышения эффективности приживления гемопоэтических стволовых клеток после трансплантации
CR20150585A (es) Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares
WO2017136731A8 (en) Rapaglutins, novel inhibitors of glut and use thereof
CL2020003447A1 (es) Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20220617